Literature DB >> 18668584

Small-vessel vasculitis surrounding an uninflamed temporal artery: a new diagnostic criterion for polymyalgia rheumatica?

Denis Chatelain1, Pierre Duhaut, Robert Loire, Sylvie Bosshard, Hélène Pellet, Jean-Charles Piette, Henri Sevestre, Jean-Pierre Ducroix.   

Abstract

OBJECTIVE: To assess the prevalence and clinical significance of small-vessel vasculitis (SVV) surrounding an uninflamed temporal artery (TA) in patients diagnosed as having giant cell (temporal) arteritis (GCA) and/or polymyalgia rheumatica (PMR).
METHODS: Patients with GCA and/or PMR (n = 490) were included in this multicenter prospective study. Slides of TA biopsy specimens were reviewed by 2 pathologists who were blinded with regard to clinical information. SVV was defined as aggregates of mononuclear inflammatory cells surrounding a capillary, distant from an uninflamed temporal artery. Clinical and biologic data of patients in the SVV group (n = 35) were compared with data of patients with biopsy-proven GCA (n = 280) and with negative TA biopsy findings (n = 175).
RESULTS: SVV was diagnosed in 18 women and 17 men (mean +/- SD age 74.5 +/- 9.4 years). The group of patients with SVV had a higher proportion of men than in the entire GCA series, had systemic symptoms, headache, jaw claudication, and an abnormal temporal artery less frequently at clinical examination, but had symptoms of PMR more often than patients in the biopsy-proven GCA group (P = 2.6 x 10(-7), odds ratio 9.17 [95% confidence interval 3.44-24.4]). Levels of inflammation markers were significantly lower in the SVV group. Patients in the SVV group had fever less frequently than patients in the group with negative TA biopsy findings, but otherwise shared the same clinical (including PMR symptoms) and biologic features. Eighteen of the 94 patients with pure PMR (19%) had SVV.
CONCLUSION: SVV is often neglected by pathologists, and appears to be strongly associated with PMR symptoms in patients with a clinical diagnosis of GCA and/or PMR. However, SVV as a new diagnostic criterion for PMR must be assessed in prospective studies.

Entities:  

Mesh:

Year:  2008        PMID: 18668584     DOI: 10.1002/art.23700

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  11 in total

Review 1.  [Pathogenesis of medium- and large-vessel vasculitis].

Authors:  C M Weyand; J J Goronzy
Journal:  Z Rheumatol       Date:  2009-03       Impact factor: 1.372

Review 2.  Giant cell arteritis and polymyalgia rheumatica: current challenges and opportunities.

Authors:  Christian Dejaco; Elisabeth Brouwer; Justin C Mason; Frank Buttgereit; Eric L Matteson; Bhaskar Dasgupta
Journal:  Nat Rev Rheumatol       Date:  2017-09-14       Impact factor: 20.543

3.  Blocking the NOTCH pathway inhibits vascular inflammation in large-vessel vasculitis.

Authors:  Kisha Piggott; Jiusheng Deng; Kenneth Warrington; Brian Younge; Jessica T Kubo; Manisha Desai; Jörg J Goronzy; Cornelia M Weyand
Journal:  Circulation       Date:  2011-01-10       Impact factor: 29.690

Review 4.  The immunopathology of giant cell arteritis: diagnostic and therapeutic implications.

Authors:  Cornelia M Weyand; Y Joyce Liao; Jörg J Goronzy
Journal:  J Neuroophthalmol       Date:  2012-09       Impact factor: 3.042

Review 5.  Vascular damage in giant cell arteritis.

Authors:  Kisha Piggott; Valerie Biousse; Nancy J Newman; Jörg J Goronzy; Cornelia M Weyand
Journal:  Autoimmunity       Date:  2009-11       Impact factor: 2.815

6.  Toll-like receptors 4 and 5 induce distinct types of vasculitis.

Authors:  Jiusheng Deng; Wei Ma-Krupa; Andrew T Gewirtz; Brian R Younge; Jörg J Goronzy; Cornelia M Weyand
Journal:  Circ Res       Date:  2009-01-15       Impact factor: 17.367

7.  Identification of target antigens of anti-endothelial cell and anti-vascular smooth muscle cell antibodies in patients with giant cell arteritis: a proteomic approach.

Authors:  Alexis Régent; Hanadi Dib; Kim H Ly; Christian Agard; Mathieu C Tamby; Nicolas Tamas; Babette Weksler; Christian Federici; Cédric Broussard; Loïc Guillevin; Luc Mouthon
Journal:  Arthritis Res Ther       Date:  2011-06-28       Impact factor: 5.156

Review 8.  Giant Cell Arteritis and Polymyalgia Rheumatica: 2016 Update.

Authors:  Gideon Nesher; Gabriel S Breuer
Journal:  Rambam Maimonides Med J       Date:  2016-10-31

Review 9.  Review: What Is the Current Evidence for Disease Subsets in Giant Cell Arteritis?

Authors:  Kornelis S M van der Geest; Maria Sandovici; Yannick van Sleen; Jan-Stephan Sanders; Nicolaas A Bos; Wayel H Abdulahad; Coen A Stegeman; Peter Heeringa; Abraham Rutgers; Cees G M Kallenberg; Annemieke M H Boots; Elisabeth Brouwer
Journal:  Arthritis Rheumatol       Date:  2018-07-30       Impact factor: 10.995

10.  Clinical comparisons of patients with giant cell arteritis with versus without fever at onset.

Authors:  Yun Zhang; Dongmei Wang; Yue Yin; Hongwei Fan; Wen Zhang; Xuejun Zeng
Journal:  J Int Med Res       Date:  2019-09-23       Impact factor: 1.671

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.